{"id":1781,"date":"2016-06-17T05:26:01","date_gmt":"2016-06-17T05:26:01","guid":{"rendered":"http:\/\/zestmag.com\/online\/?p=1781"},"modified":"2016-06-17T05:26:01","modified_gmt":"2016-06-17T05:26:01","slug":"fycompa-perampanel-oral-suspension-now-an-option-for-patients-with-epilepsy","status":"publish","type":"post","link":"http:\/\/zestmag.com\/online\/fycompa-perampanel-oral-suspension-now-an-option-for-patients-with-epilepsy\/","title":{"rendered":"FYCOMPA (perampanel) Oral Suspension now an option for patients with epilepsy"},"content":{"rendered":"<p><strong>Eisai Inc. announced the availability of FYCOMPA\u00a0(perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty swallowing tablets or prefer liquids.<\/strong><\/p>\n<p><a href=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/06\/Fycompa.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-1782\" src=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/06\/Fycompa.jpg\" alt=\"Fycompa\" width=\"622\" height=\"864\" srcset=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/06\/Fycompa.jpg 622w, http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/06\/Fycompa-216x300.jpg 216w\" sizes=\"auto, (max-width: 622px) 100vw, 622px\" \/><\/a><\/p>\n<p>FYCOMPA CIII is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. This new option, which comes in a single bottle with an adapter and syringes to measure the right dose, was approved by the U.S. Food and Drug Administration (FDA) on <span class=\"xn-chron\">April 29, 2016<\/span>.<\/p>\n<p>&#8220;Swallowing tablets can be a real concern for some patients with epilepsy,&#8221; said <span class=\"xn-person\">Lynn Kramer<\/span>, M.D., chief clinical officer and chief medical officer, Neurology Business Group, Eisai. &#8220;We are proud to offer this new option, which reinforces Eisai&#8217;s ongoing commitment to advancing epilepsy care and addressing the unmet medical needs of patients and their families.&#8221;<\/p>\n<p>FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.<\/p>\n<p>FYCOMPA is an oral medication and the first and only FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The precise mechanism by which FYCOMPA exerts its antiepileptic effects in humans has not been fully elucidated.<\/p>\n<p>FYCOMPA is supplied as 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablets, and now in an oral suspension formulation. FYCOMPA has been designated by the U.S. Drug Enforcement Administration as a federally-controlled substance (CIII).<\/p>\n<p>FYCOMPA, approved in 47 countries, was discovered and developed by Eisai. Over 60,000 patients globally have been treated with FYCOMPA.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Inc. announced the availability of FYCOMPA (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty swallowing tablets or prefer liquids.<\/p>\n","protected":false},"author":3,"featured_media":1782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[1013,1014,1016,1015,1012],"class_list":["post-1781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-product-showcase","tag-epilepsy","tag-fycompa","tag-medication","tag-medicine","tag-perampanel"],"_links":{"self":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/comments?post=1781"}],"version-history":[{"count":1,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1781\/revisions"}],"predecessor-version":[{"id":1783,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1781\/revisions\/1783"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media\/1782"}],"wp:attachment":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media?parent=1781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/categories?post=1781"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/tags?post=1781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}